NTT
18.12.2019 07:55:13 CET | Business Wire | Press release
In recent times, there has been a growing demand for companies worldwide to strengthen their compliance and risk management. To help our clients manage these requirements, NTT Group, represented by NTT Advanced Technology Corporation (hereinafter, NTT-AT), Everis Spain S.L.U. (hereinafter, everis) of NTT DATA Corporation, itelligence AG (hereinafter, itelligence) of NTT DATA Corporation are announcing a compliance management solution using robotic process automation (RPA). This solution aggregates and analyses data from internal HR and compliance on-premise and cloud-based systems, supporting customer initiatives to strengthen responsibility and internal governance control. The NTT Group plans to start providing this service in the second quarter of 2020.
Due to stricter regulations across many industries, particularly the financial industry, businesses are facing the threat of multi-regime controls and high fines by local authorities. Due to the complexity of the regulations and reporting requirements, these institutions are facing problems to identify compliance issues, along with a lack of transparency in governance. This often leads to increased manual workload, process time and paperwork due to the complexity of their IT environment.
The integrated solution provided by NTT Group combines; the RPA tool "WinActor ® (*1) " of NTT-AT, the SMCR solution of everis, and the consulting and the integration capabilities of itelligence to achieve the combination of reducing complex manual operations and coordination of compliance-related data managed across multiple systems, such as Excel (*2) and existing systems.
This solution will initially be provided as a compliance management solution for the “Senior Managers and Certification Regime (SMCR)" in the UK and will be expanded outside the UK in response to regulations and to support clients compliance and governance management globally.
NTT helps its clients accelerate their digital transformation journey by implementing innovative technologies, such as WinActor® .
Notes:
About "WinActor®
"
WinActor is a robotic process automation (RPA) tool which has been developed using the in-house technologies by NTT Access Network service system laboratories and has been achieved into commercialization.
WinActor records and automates various types of human operations such as those via Windows (*2)
application, Web Application and so on. It runs automatically routine repetitive tasks and large volume works instead of or collaborating with human. Additionally, by changing the existing jobs into new automatic work style, it would bring out a large value in business perspective such as efficiency, quality and cost effectiveness without modifying any software of existing system.
WinActor has been rapidly introduced and spread since 2017 especially in the organizations which seek for “Work style revolution” regardless the type of industry and size of the company. Currently, in November end of 2019, more than 4,200 companies have introduced WinActor.
For more information, please refer to https://winactor.biz/
.
(*1) "WinActor" is a registered trademark of NTT Advanced Technology Corporation.
(*2) "Excel", “Windows” is registered trademarks or trademarks of Microsoft Corporation in the US and/or other countries.
About NTT
For more information on NTT, visit www.global.ntt/
For more information on NTT-AT, visit www.ntt-at.com/
For more information on everis, visit www.everis.com/global/en
For more information on itelligence, visit itelligencegroup.com/us/
For more information on the solution, visit uk.nttdata.com/SMCR
View source version on businesswire.com: https://www.businesswire.com/news/home/20191217005950/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom